Seaport Hotel Boston
Boston, MA
Jacqueline DiRamio spoke on a panel, “International Considerations in Your Life Sciences IP Due Diligence Review,” at the 8th Annual Summit on Life Sciences IP Due Diligence on December 4 in Boston. The session explored the importance of understanding international IP regulations—from the U.S. to the EU and China.
The session included:
- Asia
- Tracking and surveying the status of deal-making with China
- Identifying ownership and inventorship challenges with China and their impact on freedom to operate
- Examining new Chinese patent linkage systems and what it means to be “first to enter”
- Understanding U.S. international trade policy and its effect on life sciences IP
- BIOSECURE Act
- Tariffs
- Privacy laws
- Proposed EOs limiting China’s ability to enforce IP in the U.S.
- Understanding how all these concerns collectively can impact an IP due diligence review
- Europe
- Analyzing recent UPC decisions and their impact on international IP to understand where value may be lost
- Identifying the distinctions between decisions made at the UPC vs. the IPO to anticipate IP challenges that may impact IP validity during a diligence review
- Comparing PTE and loss of exclusivity between the U.S. and the EU to determine IP longevity
- Factoring in SPC eligibility as a point of diligence review
Learn more about the conference here.